From the Department of Radiology, University Hospital of Basel, 4048 Basel, Switzerland (C.G.G., M.M., B.S., D.J.W., E.M.M., T.J.H., D.T.B.); and Center for Advanced Imaging Innovation and Research, Bernard and Irene Schwartz Center for Biomedical Imaging, Department of Radiology, New York University School of Medicine, New York, NY (T.K.B.).
Radiology. 2019 Nov;293(2):317-326. doi: 10.1148/radiol.2019190187. Epub 2019 Sep 24.
Background Gadoxetate disodium has been associated with various respiratory irregularities at arterial imaging MRI. Purpose To measure the relationship between gadolinium-based contrast agent administration and irregularities by comparing gadoxetate disodium and gadoterate meglumine at free breathing. Materials and Methods This prospective observational cohort study (January 2015 to May 2017) included consecutive abdominal MRI performed with either gadoxetate disodium or gadoterate meglumine enhancement. Participants underwent dynamic imaging by using the golden-angle radial sparse parallel sequence at free breathing. The quantitative assessment evaluated the aortic contrast enhancement, the respiratory hepatic translation, and the k-space-derived respiratory pattern. Analyses of variance compared hemodynamic metrics, respiratory-induced hepatic motion, and respiratory parameters before and after respiratory gating. Results A total of 497 abdominal MRI examinations were included. Of these, 338 participants were administered gadoxetate disodium (mean age, 59 years ± 15; 153 women) and 159 participants were administered gadoterate meglumine (mean age, 59 years ± 17; 85 women). The arterial bolus of gadoxetate disodium arrived later than gadoterate meglumine (19.7 vs 16.3 seconds, respectively; < .001). Evaluation of the hepatic respiratory translation showed respiratory motion occurring in 70.7% (239 of 338) of participants who underwent gadoxetate-enhanced examinations and in 28.9% (46 of 159) of participants who underwent gadoterate-enhanced examinations ( < .001). The duration of motion irregularities was longer for gadoxetate than for gadoterate (19.2 seconds vs 17.2 seconds, respectively) and the motion irregularities were more severe ( < .001). Both the respiratory frequency and amplitude were shorter for participants administered gadoxetate from the prebolus phase to the late arterial phase compared with gadoterate ( < .001). Conclusion The administration of two different gadolinium-based contrast agents, gadoxetate and gadoterate, at free-breathing conditions potentially leads to respiratory irregularities with differing intensity and onset. © RSNA, 2019
背景 钆塞酸二钠在动脉成像 MRI 中与各种呼吸不规则有关。目的 通过比较自由呼吸下的钆塞酸二钠和钆特酸葡胺，来测量对比剂给药与不规则之间的关系。材料与方法 本前瞻性观察队列研究（2015 年 1 月至 2017 年 5 月）纳入了连续进行的腹部 MRI 增强检查，分别使用钆塞酸二钠或钆特酸葡胺增强。受检者在自由呼吸下进行了黄金角度径向稀疏平行序列的动态成像。定量评估评估了主动脉对比增强、呼吸时肝脏平移和呼吸模式的 k 空间衍生。在呼吸门控前后比较了血流动力学指标、呼吸引起的肝运动和呼吸参数。结果 共纳入 497 例腹部 MRI 检查，其中 338 例患者给予钆塞酸二钠（平均年龄 59 岁±15；153 例女性），159 例患者给予钆特酸葡胺（平均年龄 59 岁±17；85 例女性）。钆塞酸二钠的动脉推注比钆特酸葡胺晚（分别为 19.7 秒和 16.3 秒； <.001）。评估肝呼吸平移发现，在接受钆塞酸增强检查的 338 例受检者中，有 70.7%（239 例）发生呼吸运动，而在接受钆特酸增强检查的 159 例受检者中，有 28.9%（46 例）发生呼吸运动（ <.001）。与钆特酸相比，钆塞酸的运动不规则持续时间更长（分别为 19.2 秒和 17.2 秒），且运动不规则更严重（ <.001）。从推注前阶段到晚期动脉期，接受钆塞酸的受检者的呼吸频率和幅度均短于接受钆特酸的受检者（ <.001）。结论 在自由呼吸条件下，给予两种不同的钆对比剂（钆塞酸和钆特酸）可能会导致不同强度和起始的呼吸不规则。©RSNA，2019
